Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + durvalumab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Surufatinib + durvalumab is an investigational combination regimen being studied for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). **Surufatinib** (Sulanda) is a small-molecule multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF1R). By inhibiting these pathways, surufatinib provides anti-angiogenic activity and modulates the tumor microenvironment by reducing tumor-associated macrophages. **Durvalumab** (Imfinzi) is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to restore T-cell mediated anti-tumor immune responses. The combination aims to leverage the synergistic potential of multi-kinase inhibition and immune checkpoint blockade to improve clinical outcomes in solid tumors.
- Brand names
- SulandaImfinzi
- Other names
- surufatinib + durvalizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + durvalumab.